STAT Plus: Experts parse Biogen’s Alzheimer’s data: Does the treatment work, or is it a mirage?
Beyond the grabby headlines, punchy tweets, and stock market bounces, Biogen’s surprise resuscitation of a…
Author: STAT
Opinion: Specialization improves return on capital in the life sciences
Executives who work for health care and life sciences organizations typically make strategic decisions based…
Opinion: Advancing AI in health care: It’s all about trust
Three years ago, artificial intelligence pioneer Geoffrey Hinton said, “We should stop training radiologists now….
A livestock-poison-turned-drug might save her from endless cancer surgeries. But if she helps test it, could she afford to keep taking it?
PHILADELPHIA — What propelled Kaylene Sheran up to the microphone was an overwhelming exhaustion of…
.jpg)
Alzheimer’s patients in Biogen trial, jolted by revival of drug, press for access once again
When Jeff Borghoff saw the article Tuesday morning, the first thing he did was double-check…
STAT Plus: Investors are deeply skeptical of Biogen’s Alzheimer’s claims. They still think it could win approval
“This is basically a game of corporate three-card monte.” Likening Biogen to a sidewalk confidence…
STAT Plus: Pharmalittle: Biogen resurrects an Alzheimer’s drug; last-minute settlement in a big opioid trial
Hello, everyone, and how are you today? We are doing just fine, thank you, now…
Novartis gene therapy brings in $160 million, beating expectations
Zolgensma, a lifesaving treatment for infants and the world’s most expensive drug, has been used…
In shocking reversal, Biogen to submit experimental Alzheimer’s drug for approval
In a shocking reversal, Biogen on Tuesday said that it would resurrect an Alzheimer’s drug…
Opinion: The HRA rule could be a game changer for health insurance
The open enrollment season for health insurance is close at hand, providing many people with…
Opinion: Restaurants are using AI to listen in on social media. They want to know how you are feeling
You probably don’t know it yet, but you’ve got some new social media followers. And…
.jpg)
STAT Plus: This small biotech is suing the Trump administration to get its drug covered
WASHINGTON — A small Cambridge-based biotech, Akebia Therapeutics, is in the midst of a massive,…
How Joe Grogan, a former pharma lobbyist, upended Trump’s drug pricing agenda
WASHINGTON — As the Marine Band warmed up and White House aides scurried to set…
STAT Plus: Consumers sue Sanofi and other drug makers over Zantac link to a possible carcinogen
The various companies that made and sold Zantac over the past 36 years are being…
STAT Plus: Seattle Genetics to seek approval for new breast cancer pill after positive clinical trial results
Breast cancer patients treated with a combination of medicines that included an experimental pill from…
Opinion: Put communities at the center of universal health coverage
The Political Declaration on Universal Health Coverage, adopted recently at the United Nations General Assembly,…
Opinion: Rapid expansion of telehealth comes with new challenges
It’s a boom time for telehealth. State and federal policies governing this new way to…
STAT Plus: A biotech real estate firm wants a new slogan. WeWork says not so fast
Embattled office-subleasing and “consciousness-elevating” company WeWork has a bone to pick with a biotech giant….
Two down, one to go: After decades-long campaign, type 3 polioviruses are set to be eradicated
After months of bad news, the international army of people who have been working for…
STAT Plus: Biotech worries new trade rules could sap foreign investment
The biotech industry is worried that a proposed federal rule could further dampen overseas investment…
STAT Plus: Sanofi pulls Zantac from the U.S., joining a growing list of companies recalling heartburn meds
One month after numerous companies began extensive recalls of their heartburn drugs because traces of…
Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing
When 23andMe received government permission in 2017 to sell health-related genetic testing, it came with…
Listen: Pharma’s future in China, CRISPR meets Netflix, & where VC dollars come from
Should drug companies be free-speech advocates? Is your retirement dependent on CRISPR? And how useful…
Pelosi: Democrats will name marquee drug pricing bill for late Rep. Cummings
WASHINGTON — House Democrats’ signature legislation to lower the cost of prescription drugs will be…
STAT Plus: CSL sues a former employee and rival over alleged theft of trade secrets
Last April, a CSL Behring senior medical affairs director named Joseph Chiao began talking to…
STAT Plus: Pharmalittle: Five companies offer $50 billion deal to settle opioid suits; FDA approves record number of generics
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT Plus: Sean Parker, billionaire and philanthropist, gets an immunotherapy company off the ground
Silicon Valley billionaire Sean Parker, founder of Napster and an early investor in Facebook, has…
Opinion: Pelosi’s drug pricing plan puts medical innovation at risk
The future of medical innovation in America is at a crossroads. Biopharmaceutical science is accelerating…
STAT Plus: Most state Medicaid programs continue to restrict access to hepatitis C medicines
Despite guidance from the federal government, most state Medicaid programs continue to deny hepatitis C…
STAT Plus: Blueprint and Ipsen to work together on treatment for ultra-rare genetic disorder
Blueprint Medicines will receive $25 million to collaborate with the French drug maker Ipsen on…
Here’s a brain teaser: Surprising study shows reduced neuronal activity extends life
Say this about the kinds of molecular mayhem that we know underlie aging: Mechanisms like…
Opinion: CBO estimate on Pelosi drug bill misses its long-term impact on health
House Democrats got an early Halloween treat with the Congressional Budget Office’s review of HR…
An ‘unprecedented’ analysis underlines profound failure to study African genomes
It has become the geneticist’s version of, “What, me not inclusive? But I have a…
STAT Plus: Pharmalittle: Opioid trial underway as distributors try to settle; patients beg DEA to reconsider opioid production cuts
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
Archived chat: a discussion with 2019 Nobel laureate Dr. William Kaelin
Dr. William Kaelin of Harvard Medical School went to sleep at his usual bedtime on…
STAT Plus: A murky approach to tracking 340B drugs and Medicaid may yield double discounts in some states
Amid ongoing controversy over a federal drug discount program for safety-net hospitals, a new survey…
STAT Plus: Pharmalittle: House progressives seek to change Pelosi bill; shortage of a critical cancer drug for kids
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT Plus: ‘Gene therapy headwinds’ are blamed for biotech stock woes
Blame a slump in gene therapy stocks in the second half of the year for…
Ancestry launches consumer genetics tests for health, intensifying rivalry with 23andMe
Ancestry, the consumer genetics company that has until now focused on helping people understand their…
Opinion: Wanted: better policies and incentives to revitalize R&D for new antimicrobial drugs
In the not-too-distant future that we could be facing — one with rampant, uncontrollable, multidrug-resistant…
Opinion: Using CRISPR to edit eggs, sperm, or embryos does not save lives
The startling announcement by He Jiankui almost one year ago that he had created the…
STAT Plus: House progressives plot overhaul of Pelosi drug pricing bill
WASHINGTON — In the eyes of progressive lawmakers, House Speaker Nancy Pelosi’s drug pricing legislation…
STAT Plus: Congressional Budget Office says Pelosi drug pricing bill could save $345 billion
A controversial prescription drug pricing bill championed by House Speaker Nancy Pelosi (D-Calif.) would reduce…
STAT Plus: FDA bid to bolster generic competition and combat shortages isn’t working — yet
Although the Food and Drug Administration has maintained that additional generic approvals should promote competition…
STAT Plus: Pharmalittle: Judge orders pause in suits against Purdue and Sacklers; Teva must face opioid trial
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Opinion: FDA is smashing the status quo for regulatory science
A recent press release from the Food and Drug Administration titled “Reorganization of the Office…
Opinion: Accounting for hope: using ‘mean survival gain’ to price new cancer drugs
Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight….
An updated guide to the changing science of flu shots
Flu shot season is upon us. Three years ago, STAT laid out some of the…
Vaping-related illness has a new name: EVALI
The vaping-related condition that has sickened hundreds of people has a new name: EVALI, or…
Sun Pharma is accused of distributing medicines in Washington state without a license
The Washington Department of Health is reviewing a complaint that Sun Pharmaceuticals (SUNPHARMA) has been…